Fri.Dec 31, 2021

article thumbnail

No convincing scientific evidence that hangover cures work, according to new research

Scienmag

A new systematic review has found only very low-quality evidence that substances claiming to treat or prevent alcohol-induced hangover work. The researchers call for more rigorous scientific exploration of the effectiveness of these remedies for hangovers to provide practitioners and the public with accurate evidence-based information on which to make their decisions.

article thumbnail

Alzheimer's Drug Aduhelm Faces Crucial Medicare Decision

NY Times

Medicare officials are trying to determine whether to cover Aduhelm, which the F.D.A. approved despite unclear evidence that it helps patients.

Drugs 72
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Teva will appeal opioid liability ruling in New York trial

pharmaphorum

The jury in a new York trial has found that Teva Pharmaceuticals played a role in fuelling the opioid crisis in the US, and should be held liable for damages, which will be decided later. The decision came after eight days of deliberation by the jurors, and almost six months of legal jousting between the drugmaker and its counsel and lawyers for the state of New York and two of its counties, Suffolk and Nassau.

Trials 52
article thumbnail

Wearables in Clinical Trials: An Overview of Challenges

Cloudbyz

Wearable Tech-What’s It All About? Let’s start from the very beginning. What are people talking about when they say “wearables”, “wearable biosensors”, “wearable devices”, or “wearable technology” in clinical trials? In the most basic sense, all these terms refer to relatively mobile devices that you can wear on your person; designed to measure specific biological parameters in your body.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

R1 RCM to Present at the 40th Annual J.P. Morgan Healthcare Conference

BioTech 365

R1 RCM to Present at the 40th Annual J.P. Morgan Healthcare Conference R1 RCM to Present at the 40th Annual J.P. Morgan Healthcare Conference MURRAY, Utah, Dec. 31, 2021 (GLOBE NEWSWIRE) — R1 RCM Inc.

40
article thumbnail

Which pharmaceutical companies have the most drug patents in Spain?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Spain. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Spain? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98

More Trending

article thumbnail

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BioTech 365

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 31, 2021 (GLOBE NEWSWIRE) — Baudax Bio, Inc.

40
article thumbnail

Sproutly Issues Shares in Lieu of Semi-Annual Interest Payment

BioTech 365

Sproutly Issues Shares in Lieu of Semi-Annual Interest Payment Sproutly Issues Shares in Lieu of Semi-Annual Interest Payment NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES VANCOUVER, British Columbia–(BUSINESS WIRE)–Sproutly Canada, Inc.

40
article thumbnail

Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement

BioTech 365

Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement – Growing body of evidence validates … Continue reading →

article thumbnail

BIOLIFE4D Announces Intention to Submit Draft Registration Statement for Underwritten Public Offering of Common Stock

BioTech 365

BIOLIFE4D Announces Intention to Submit Draft Registration Statement for Underwritten Public Offering of Common Stock BIOLIFE4D Announces Intention to Submit Draft Registration Statement for Underwritten Public Offering of Common Stock BUFFALO GROVE, Ill., Dec.

40
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

President Biden, You Can’t Vaccinate the World Without Breaking Patents, Says AHF

BioTech 365

President Biden, You Can’t Vaccinate the World Without Breaking Patents, Says AHF President Biden, You Can’t Vaccinate the World Without Breaking Patents, Says AHF LOS ANGELES–(BUSINESS WIRE)–As the demand for COVID-19 vaccine booster shots is growing across wealthy countries, an … Continue reading →

article thumbnail

Pipeline Update on gRAD Tests

BioTech 365

Pipeline Update on gRAD Tests Pipeline Update on gRAD Tests December 31, 2021News release Pipeline Update on gRAD Tests BioPorto A/S (BioPorto) is supporting Rigshospitalet (RH), Copenhagen, with quantitative thrombomodulin tests based on its generic Rapid Assay Device (gRAD) technology.

40
article thumbnail

Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

BioTech 365

Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc.

40
article thumbnail

Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800

BioTech 365

Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800 Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800 The Phase 1 Study Will be Comprised of Two Parts: Phase 1a Dose-escalation that will Evaluate the Safety and Tolerability of NXP800 … Continue reading →

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

PAION SUBMITS EXTENSION APPLICATION OF MARKETING AUTHORIZATION FOR REMIMAZOLAM IN THE INDICATION GENERAL ANESTHESIA TO THE EUROPEAN MEDICINES AGENCY

BioTech 365

DGAP-News: PAION AG / Key word(s): Regulatory Admission 31.12.2021 / 12:38 The issuer is solely responsible for the content of this announcement.

article thumbnail

Grant of warrants

BioTech 365

Grant of warrants Grant of warrants December 31, 2021Announcement no.

40